221MO Stereotactic body radiotherapy (SBRT) followed by durvalumab in early-stage non-small cell lung cancer (NSCLC) patients: Results from a randomized phase II trial (ASTEROID)
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: SBRT is the standard treatment for early-stage NSCLC patients, unfit for surgery, and SBRT is associated with excellent results in terms of local control. However, an important proportion of patients develop distant metastases over time. Adjuvant chemotherapy is rarely administered due to lack of data and the frailty of this population. Theoretically, immunotherapy is an attractive option, often being well tolerated and with a potential synergistic effect in combination with radiation. The ASTEROID trial aimed to assess whether the addition of durvalumab improves tumour control after SBRT in peripheral T1-2N0M0 tumours.
Source: ESMO Open
Institutions: Sahlgrenska University Hospital, University of Gothenburg, Karolinska University Hospital, Karolinska Institutet, Gävle Hospital, Oslo University Hospital, University of Oslo, Linköping University Hospital, Umeå University, Lund University, Skåne University Hospital, Sunderby sjukhus, Ålesund Hospital, Turku University Hospital, Norwegian University of Science and Technology, University Hospital of North Norway
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W7138235105
FWCI:
Cites:
Cited by:
Related to: